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Background
DTG is a once-daily integrase inhibitor that in combination
with ABC/3TC, demonstrated superior efficacy with favor-
able tolerability over TDF/FTC/EFV (SINGLE study) at
48 weeks. EFV is associated with reduced Vitamin D levels
through CYP450 enzyme induction; TDF has been asso-
ciated with decreased bone mineral density (BMD). Antire-
troviral treatment (ART) initiation is characterized by
initial rapid decline in bone mineral density (BMD) that
subsequently stabilizes. Bone turnover markers are
increased during these BMD changes.
Methods
In the double-blind SINGLE study (table 1) we measured
markers of bone turnover (bone-specific alkaline
phosphatase, C-termial telopeptide type 1 collagen,
osteocalcin, and procollagen type 1 N-propeptide) &
Vitamin D at baseline (BL) and at 48 weeks. ANCOVA
analyses were adjusted for the following factors age, sex,
HIV RNA, CD4+ cell count, BL biomarker level, BMI,
smoking status, and Vitamin D supplementation.
Results
833 subjects were analyzed: 84% males; 68% whites.
Mean BL VL: 4.7 log10 c/mL; 32% VL>100,000 c/mL and
mean BL CD4 cell count = 350 cells/mm3. Bone markers
increased in both groups but the increases were signifi-
cantly greater in subjects treated with TDF/FTC/EFV.
Vitamin D levels decreased in both treatment groups; the
differences were not significant between groups.












15% 60% 0.720 [0.685-0.756] <0.001
C-terminal telopeptide for
type 1 collagen
33% 68% 0.789 [0.747-0.832] <0.001
Osteocalcin 22% 48% 0.827 [0.779-0.878] <0.001
Procollagen type 1 N-
propeptide
30% 66% 0.784 [0.749- 0.821] <0.001
Vitamin D (25-hydroxy-
Vitamin D)
-7% -10% 1.036 [0.970-1.107] P=0.292
*adjusted percent change from baseline=100 X adjusted geometric mean of (week 48/baseline)-100
**GMR= (DTG+ABC/3TC+100) / (TDF/FTC/EFV+100)
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Conclusions
After 48 weeks, significantly greater changes from base-
line were observed for all bone markers in subjects
receiving TDF/FTC/EFV, indicating more active bone
turnover when compared to changes seen in subjects
receiving DTG + ABC/3TC. These differences may cor-
relate with known TDF-associated changes in BMD over
time and further study of the potential advantages of a
DTG+ABC/3TC regimen appear warranted.
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